Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 4;11(7):1898.
doi: 10.3390/biomedicines11071898.

New Onset Autoimmune Diseases after the Sputnik Vaccine

Affiliations

New Onset Autoimmune Diseases after the Sputnik Vaccine

Olga Vera-Lastra et al. Biomedicines. .

Abstract

The vertiginous advance for identifying the genomic sequence of SARS-CoV-2 allowed the development of a vaccine including mRNA-based vaccines, inactivated viruses, protein subunits, and adenoviral vaccines such as Sputnik. This study aims to report on autoimmune disease manifestations that occurred following COVID-19 Sputnik vaccination. Patients and Methods: A retrospective study was conducted on patients with new-onset autoimmune diseases induced by a post-COVID-19 vaccine between March 2021 and December 2022, in two referral hospitals in Mexico City and Argentina. The study evaluated patients who received the Sputnik vaccine and developed recent-onset autoimmune diseases. Results: Twenty-eight patients developed recent-onset autoimmune diseases after Sputnik vaccine. The median age was 56.9 ± 21.7 years, with 14 females and 14 males. The autoimmune diseases observed were neurological in 13 patients (46%), hematological autoimmune manifestations occurred in 12 patients (42%), with thrombotic disease observed in 10 patients (28%), and autoimmune hemolytic anemia in two patients (7.1%). Rheumatological disorders were present in two patients (7.1%), and endocrine disorders in one patient (3.5%). Principio del formulario Conclusion: Although the COVID-19 Sputnik vaccine is generally safe, it can lead to adverse effects. Thrombosis and Guillain-Barre were the most frequent manifestations observed in our group of patients.

Keywords: Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA); COVID-19 vaccines; adverse events; sputnik vaccines; systemic autoimmune diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An intense reaction is observed in the patient’s cerebrospinal fluid autoIgGs against proteins located in the muscle sarcolemma, corresponding to aquaporins (green dots; white arrow) and red/yellow dots representing muscle cell nuclei.
Figure 2
Figure 2
(A) MRI in FLAIR, axial plane: a hyperintense lesion is observed in the parieto-occipital region with an ovoid shape of 6 mm, in relation to a single lesion with demyelinating characteristics in a patient with Neuromyelitis Optica Spectrum Disorder (NMOSD). (B) MRI is observed in the T2-weighted cervical spine, sagittal plane: multifocal lesion with a tendency to an extensive longitudinal pattern, with involvement of segments C2, C3, C4, and C7, in relation to myelitis with inflammatory characteristics due to NMOSD of previous patients with a brain lesion. (C) Sagittal T2 MRI: cervical and thoracic spine that shows continuous signal hyperintensity that involves the spinal cord from cervical to T3–T4 (arrows) in another patient with NMOSD.

Similar articles

Cited by

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615 . doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Chen Y., Xu Z., Wang P., Li X., Shuai Z., Ye D., Pan H. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386–401. doi: 10.1111/imm.13443. - DOI - PubMed
    1. Adu P., Popoola T., Medvedev O.N., Collings S., Mbinta J., Aspin C., Simpson C.R. Implications for COVID-19 vaccine uptake: A systematic review. J. Infect. Public Health. 2023;16:441–466. doi: 10.1016/j.jiph.2023.01.020. - DOI - PMC - PubMed
    1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and efficacy of a rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomized controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8. - DOI - PMC - PubMed
    1. Erra L., Uriarte I., Colado A., Paolini M.V., Seminario G., Fernández J.B., Tau L., Bernatowiez J., Moreira I., Vishnopolska S., et al. COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity. J. Clin. Immunol. 2022;43:271–285. doi: 10.1007/s10875-022-01382-7. - DOI - PMC - PubMed

LinkOut - more resources